A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells.
One form of multidrug resistance is due to the expression of a 170-kDa energy-dependent drug efflux pump called P-glycoprotein in the plasma membranes of human cancer cells. We have prepared conjugates of Pseudomonas toxin with the anti-P-glycoprotein monoclonal antibody MRK-16. These anti-P-glycoprotein-toxin conjugates specifically kill multidrug-resistant human KB cells. Similar conjugates could be useful in cancer therapy to reduce or eliminate multidrug-resistant tumor populations in tumors intrinsically resistant to chemotherapy or in populations that become resistant during combination chemotherapy.
D036002:ADP Ribose Transferases; D000911:Antibodies, Monoclonal; D001427:Bacterial Toxins; D003078:Colchicine / Q000494:pharmacology*; D004317:Doxorubicin / Q000494:pharmacology*; D004351:Drug Resistance; D005098:Exotoxins / Q000633:toxicity*; D006801:Humans; D000922:Immunotoxins / Q000633:toxicity*; D007624:KB Cells; D011549:Pseudomonas; D014747:Vinblastine / Q000494:pharmacology*; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A
D036002:ADP Ribose Transferases; D000911:Antibodies, Monoclonal; D001427:Bacterial Toxins; D003078:Colchicine; D004317:Doxorubicin; D005098:Exotoxins; D000922:Immunotoxins; D014747:Vinblastine; D037521:Virulence Factors; D000097668:Pseudomonas aeruginosa Exotoxin A